Vnitr Lek 2007, 53(9):931-933

Invazivní houbové infekce u nemocných po transplantaci kmenových buněk krvetvorby: vývoj v diagnostice, prevenci a léčbě v posledním desetiletí - editorial

P. Cetkovský
Klinický úsek, vedoucí doc. MUDr. Petr Cetkovský, Ph.D., Ústavu hematologie a krevní transfuze Praha, ředitel prof. MUDr. Pavel Klener, DrSc.

Received: March 28, 2007; Published: September 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cetkovský P. Invazivní houbové infekce u nemocných po transplantaci kmenových buněk krvetvorby: vývoj v diagnostice, prevenci a léčbě v posledním desetiletí - editorial. Vnitr Lek. 2007;53(9):931-933.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wingard JR Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5: 55-68.
    2. Baden LR. Prevention and therapy of fungal infections in bone marrow transplantation. Leukemia 2003; 17: 1038-1041. Go to original source... Go to PubMed...
    3. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552. Go to original source... Go to PubMed...
    4. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851. Go to original source... Go to PubMed...
    5. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14. Go to original source... Go to PubMed...
    6. Ráčil Z, Kocmanová I, Wagnerová B et al. Časná diagnostika invazivních myotických infekcí u hematoonkologických nemocných pomocí sérologických metod. Vnitř Lék 2007; 53(9): 990-999. Go to PubMed...
    7. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-429. Go to original source... Go to PubMed...
    8. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360. Go to original source... Go to PubMed...
    9. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989. Go to PubMed...
    10. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69. Go to original source... Go to PubMed...
    11. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients with amphotericin B lipid complex. Clin Infect Dis 2005; 6: 401-408. Go to original source... Go to PubMed...
    12. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.